secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2024-02-26T23:59:59+00:00
Accession:  0001140361-24-009506
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharma Reports Q4 2023 Net Loss of $59.7M; PDUFA Date for KRESLADI Set for June 30, 2024
--------------------------------------------------------------------------------

- Cash, cash equivalents and investments stood at $407.5M as of Dec 31, 2023, providing runway into 2026.
- Net loss for Q4 2023 was $59.7M ($0.64 per share); full year 2023 net loss $245.6M ($2.92 per share).
- FDA extended Priority Review of KRESLADI BLA for severe LAD-I to June 30, 2024; no advisory committee needed.
- Fanconi Anemia BLA and MAA filings remain on track for H1 2024; pipeline milestones for 2024 reaffirmed.
- Appointed R. Keith Woods to Board; he previously led commercialization of Vyvgart at argenx.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036124009506/0001140361-24-009506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036124009506/ef20022436_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-009506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer